Sam Kintz, Enliven Therapeutics CEO
October 14, 2022 07:06 AM EDT
Deals

Imara puts an end to its strug­gles as Or­biMed, 5AM-backed pre­ci­sion on­col­o­gy play­er rides the shell to Nas­daq

Amber Tong

Since its launch in 2016 out of New En­ter­prise As­so­ciates’ or­phan drug ac­cel­er­a­tor Cy­dan — and through its 2020 IPO rais­ing $75 mil­lion — Imara has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times